Search results for "Curevo Vaccine"

Eli Lilly to Acquire Seattle-Area Biotech Curevo for $1.5 Billion

Eli Lilly is set to acquire Seattle-area biotech Curevo Vaccine for up to $1.5 billion to bolster its infectious disease portfolio. The deal centers on Curevo's Phase 3-ready shingles vaccine candidate, amezosvatein, which demonstrated a more than 50% reduction in side effects during Phase 2 studies, aiming to boost vaccination rates among older adults.